LAT1 expression is closely associated with hypoxic markers and mTOR in resected non-small cell lung cancer

American Journal of Translational Research

Volumn 3, Issue 5, 2011, Pages 468-478

  Kaira, Kyoichi ^a   Oriuchi, Noboru ^b   Takahashi, Toshiaki ^a   Nakagawa, Kazuo ^a   Ohde, Yasuhisa ^a   Okumura, Takehiro ^a   Murakami, Haruyasu ^a   Shukuya, Takehito ^a   Kenmotsu, Hirotsugu ^a   Naito, Tateaki ^a   Kanai, Yoshikatsu ^c   Endo, Masahiro ^a   Kondo, Haruhiko ^a   Nakajima, Takashi ^a   Yamamoto, Nobuyuki ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

^b GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

Glucose transporter; Hypoxia; LAT1; mTOR; NSCLC

Indexed keywords

CARRIER PROTEIN; CD34 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; HEXOKINASE 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN LAT1; S6 KINASE; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CELL HYPOXIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

MAMMALIA;

EID: 80054751326     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. 18F]-fluoro-2-deoxy-Dglucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol 2010; 28: 3746-3753.
2. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Tanaka S, Ishizuka T, Kanai Y, Endou H, Nakajima T and Mori M. Prognostic significance of L-type amino acid transporter 1 expression in resectable stage IIII nonsmall cell lung cancer. Br J Cancer 2008; 98: 742-748.
3. Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E and Endou H. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem 1998; 273: 23629-23632.
4. Oxender DL, Christensen HN. Evidence for two types of mediation of neutral amino acid transport in Ehrlich cells. Nature 1963; 197: 765-767.
5. Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: Partners in crime? Seminars in Cancer Biology 2006; 15: 254-266.
6. Yamauchi K, Sakurai H, Kimura T, Wiriyasermkul P, Nagamori S, Kanai Y and Kohno N. System L amino acid transporter inhibitor enhances anti-tumor activity of cisplatin in a head and neck squamous cell carcinoma cell line. Cancer Letters 2009; 276: 95-101.
7. Imai H, Kaira K, Oriuchi N, Shimizu K, Tominaga H, Yanagitani N, Sunaga N, Ishizuka T, Nagamori S, Promchan K, Nakajima T, Yamamoto N, Mori M and Kanai Y. Inhibition of Ltype amino acid transporter 1 has antitumor activity in non-small cell lung cancer. Anticancer Res 2010; 30: 4819-4828.
8. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Tanaka S, Ishizuka T, Kanai Y, Endou H, Nakajima T and Mori M. Ltype amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms. Cancer Sci 2008; 99: 2380-2386.
9. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Nakajima T and Mori M. Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in stage I pulmonary adenocarcinoma. Lung Cancer 2009; 66: 120-126.
10. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Kawashima O, Kamide Y, Ishizuka T, Kanai Y, Nakajima T and Mori M. CD98 expression is associated with poor prognosis in resected non-small cell lung cancer with lymph node metastasis. Ann Surg Oncol 2009; 16: 3473-3481.
11. 18F-FDG uptake in nonsmall cell lung cancer. Cancer Sci 2009; 100: 753-758.
12. Vleugel MM, Greijer AE, Shvarts A, van der Groep P, van Berkel M, Aarbodem Y, van Tinteren H, Harris AL, van Diest PJ and van der Wall E. Differential prognostic impact of hypoxia induced and diffuse HIF-1 alpha expression in invasive breast cancer. J Clin Pathol 2005; 58: 172-177.
13. Elson DA, Ryan HE, Snow JW, Johnson R and Arbeit JM. Coordinate up-regulation of hypoxia inducible factor (HIF)-1a and HIF-1 target genes during multi-stage epidermal carcinogenesis and wound healing 1. Cancer Res 2000; 60: 6189-6195.
14. Ryan HE, Polni M, McNulty W, Elson D, Gassmann M, Arbeit JM and Johnson RS. Hypoxiainducible factor-1α is a positive factor in solid tumor growth. Cancer Res 2000; 60: 4010-4015.
15. Soado RJ, Li JY, Tsukamoto H and Pardridge WM. Hypoxia induces de-stabilization of the LAT1 large neural amino acid transporter mRNA in brain capillary endothelial cells. J Neurochem 2003; 85: 1037-1042.
16. Ohno H, Nakatsu Y, Sakoda H, Kushiyama A, Ono H, Fujishiro M, Otani Y, Okubo H, Yoneda M, Fukushima T, Tsuchiya Y, Kamata H, Nishimura F, Kurihara H, Katagiri H, Oka Y and Asano T. 4F2hc stabilizes GLUT1 protein and increases glucose transport activity. Am J Physiol Cell Physiol 2011; 286: C1047-1054.
17. Mountain CF. Revision in the International System for Staging Lung Cancer. Chest 1997; 11: 1710-1717.
18. Nawashiro H, Otani N, Shinomiya N, Fukui S, Ooigawa H, Shima K, Matsuo H, Kanai Y and Endou H. L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer 2006; 119: 484-492.
19. Chairoungdua A, Segawa H, Kim JY, Miyamoto K, Haga H, Fukui Y, Mizoguchi K, Ito H, Takeda E, Endou H and Kanai Y. Identification of an amino acid transporter associated with the cystinuria-related type II membrane glycoprotein. J Biol Chem 1999; 274: 28845-28848.
20. Fan X, Ross DD, Arakawa H, Ganapathy V, Tamai I and Nakanishi T. Impact of system L amino acid transporter 1 (LAT1) on proliferation of human ovarian cancer cells: A possible target for combination therapy with proliferative aminopeptidase inhibitors. Biochem Pharmacol 2010; 80: 811-8.
21. Younes M, Brown RW, Stephenson M, Gondo M and Cagle PT. Over expression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 1997; 80: 1046-1051.
22. 18F-fluoro-2-deoxy-D-glucosepositron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res 2006; 12: 97-106.
23. Sunaga N, Oriuchi N, Kaira K, Yanagitani N, Tomizawa Y, Hisada T, Ishizuka T, Endo K and Mori M. Usefulness of FDG-PET for early prediction of the response to gefitinib in nonsmall cell lung cancer. Lung Cancer 2008; 59: 203-210.